Pfizer (NYSE:PFE) licensed Novavax’s Matrix-M adjuvant technology to support future vaccine development. The company received FDA Breakthrough Therapy Designation for a combination of Sutent and ...

"The winners in life are differentiated from the losers in life because the winners never fall," Albert Bourla says. "The ...

Pfizer PFE is set to release its fourth-quarter and full-year 2025 results on Feb. 3, with investor attention focused on ...

From a valuation standpoint, Pfizer appears attractive relative to the industry and is trading below its 5-year mean. Going ...

Pfizer PFE is one of the largest and most successful drugmakers in oncology. It boasts a strong portfolio of approved cancer medicines as well as a robust pipeline of cancer candidates with a focus on ...

Pfizer is steering much of its pandemic revenue into oncology, as Chief Executive Albert ...

SAN FRANCISCO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (OLMA) (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, ...

The global oncology sector is rocketing toward $668 billion in 2034[1], partly fueled by a massive structural pivot toward gastrointestinal ...

Pfizer has spent billions of dollars on acquisitions in the past few decades. Its biggest deals include Warner-Lambert, ...